COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:


The National Cancer Institute (NCI)'s Antibody Program comprehensively characterizes affinity reagents for cancer research via its Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR). Each reagent on the Antibody Portal has been characterized by a combination of methods specific for that antibody. To view the customized antibody methods and protocols (Standard Operating Procedures) used to generate and characterize each reagent, select from the table below. Additionally, each protocol can be found on the portal by selecting an antibody of interest and opening the protocols associated with their respective characterization data.